GlobeNewswire: Avid Bioservices, Inc Contains the last 10 of 167 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:30:52ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/20/2849234/0/en/Avid-Bioservices-Announces-Receipt-of-Deficiency-Notice-from-Nasdaq-Regarding-Late-Form-10-Q.html?f=22&fvtc=4&fvtv=37267Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q2024-03-20T11:00:10Z<![CDATA[TUSTIN, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (Nasdaq:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today it received a notice (the “Notice”) on March 19, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the company that it was not in compliance with Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1) (the “Rule”) as a result of its failure to file its Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024 (the “Form 10-Q”) in a timely manner.]]>https://www.globenewswire.com/news-release/2024/03/07/2841912/0/en/Avid-Bioservices-Announces-Pricing-of-Private-Placement-of-Convertible-Notes.html?f=22&fvtc=4&fvtv=37267Avid Bioservices Announces Pricing of Private Placement of Convertible Notes2024-03-07T04:58:48Z<![CDATA[TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029 (the “2029 Notes”). In connection with the offering, the company entered into private placement purchase agreements with the several purchasers, each of whom is a “qualified institutional buyer” within the meaning of Rule 144A promulgated under the Securities Act of 1933, as amended (the “Securities Act”). The closing of the offering is subject to customary closing conditions and is expected to take place on March 12, 2024.]]>https://www.globenewswire.com/news-release/2024/03/06/2841815/0/en/Avid-Bioservices-Announces-Proposed-Private-Placement-of-Convertible-Notes.html?f=22&fvtc=4&fvtv=37267Avid Bioservices Announces Proposed Private Placement of Convertible Notes2024-03-06T21:32:07Z<![CDATA[TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes due 2029 (the “2029 Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The company expects to price the Offering before open of market on March 7, 2024.]]>https://www.globenewswire.com/news-release/2024/03/06/2841814/0/en/Avid-Bioservices-Announces-Certain-Preliminary-Financial-Results-for-Third-Quarter-Ended-January-31-2024.html?f=22&fvtc=4&fvtv=37267Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 20242024-03-06T21:31:28Z<![CDATA[TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced preliminary earnings estimates for the third quarter and nine months ended January 31, 2024.]]>https://www.globenewswire.com/news-release/2023/12/07/2792891/0/en/Avid-Bioservices-Reports-Financial-Results-for-Second-Quarter-Ended-October-31-2023.html?f=22&fvtc=4&fvtv=37267Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 20232023-12-07T21:05:38Z<![CDATA[-- Recorded Second Quarter Revenue of $25.4 Million ---- Signed $35 Million in Net New Business Orders Resulting in a Backlog of $199 Million --]]>https://www.globenewswire.com/news-release/2023/11/30/2788952/0/en/Avid-Bioservices-to-Report-Financial-Results-for-Second-Quarter-of-Fiscal-Year-2024-After-Market-Close-on-December-7-2023.html?f=22&fvtc=4&fvtv=37267Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 20232023-11-30T21:05:57Z<![CDATA[TUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2024 on December 7, 2023, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the second quarter and review recent corporate developments.]]>https://www.globenewswire.com/news-release/2023/11/08/2776212/0/en/Avid-Bioservices-Partners-With-California-Institute-for-Regenerative-Medicine-CIRM-to-Provide-CDMO-Services-for-Cell-and-Gene-Therapy-CGT-Programs.html?f=22&fvtc=4&fvtv=37267Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs2023-11-08T13:05:03Z<![CDATA[CIRM-Funded Programs to Receive Access to Avid’s Suite of World-Class CGT CDMO Services to Support Clinical Development Activities CIRM-Funded Programs to Receive Access to Avid’s Suite of World-Class CGT CDMO Services to Support Clinical Development Activities]]>https://www.globenewswire.com/news-release/2023/10/17/2761477/0/en/Avid-Bioservices-Completes-Construction-of-New-World-Class-Cell-and-Gene-Therapy-Development-and-Manufacturing-Facility.html?f=22&fvtc=4&fvtv=37267Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing Facility2023-10-17T12:05:09Z<![CDATA[Newly Launched CGMP Manufacturing Suites Undergoing Final Environmental Monitoring and Performance Qualification with Grand Opening Planned for January 2024]]>https://www.globenewswire.com/news-release/2023/09/26/2749935/0/en/Avid-Bioservices-to-Participate-in-RBC-Capital-Markets-Virtual-CDMO-Conference.html?f=22&fvtc=4&fvtv=37267Avid Bioservices to Participate in RBC Capital Markets Virtual CDMO Conference2023-09-26T20:05:51Z<![CDATA[TUSTIN, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the RBC Capital Markets Virtual CDMO Conference. Nick Green, president and chief executive officer, will be the featured speaker in a fireside chat at the conference, which will take place October 2-3, 2023.]]>https://www.globenewswire.com/news-release/2023/09/07/2739768/0/en/Avid-Bioservices-Reports-Financial-Results-for-First-Quarter-Ended-July-31-2023.html?f=22&fvtc=4&fvtv=37267Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 20232023-09-07T20:05:25Z<![CDATA[-- Recorded First Quarter Revenue of $37.7 Million ---- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million --]]>